<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0706233773
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1983
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RIFADIN CAP 150 MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIFAMPICIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="sanofi S.R.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            sanofi S.R.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J04AB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rifadin contains rifampicin, an antibiotic that can kill various types of harmful bacteria, especially those that cause tuberculosis, an infectious disease that normally attacks the lungs.<br />Rifadin can be used along with other antibiotics or other drugs such as chemotherapy agents.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contraindications:<br />Do not use Rifadin:<br />&bull; if you are allergic to the active substance or any of the other ingredients of this medicine listed in section 6;<br />&bull; if you have a condition that causes yellowing of the skin and eyes (jaundice);<br />&bull; if you are taking a medicine containing saquinavir or ritonavir, medicines used to treat HIV infection, the virus that causes AIDS (see section &ldquo;Other medicines and Rifadin&rdquo;).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Rifadin if:<br />&bull; you have liver problems;<br />&bull; you have porphyria (a rare hereditary blood metabolism disorder);</p><p>&bull; you are malnourished or elderly, or if the medicine is to be taken by a young child, particularly if another antibiotic called isoniazid is being taken at the same time.<br />&bull; you have bleeding disorders or bruise easily (as this medicine can cause blood clotting disorders);<br />&bull; you are taking other antibiotics (as certain antibiotics can increase the risk of blood clotting disorders);<br />If you are not sure whether any of the above apply to you, talk to your doctor or pharmacist before taking Rifadin.<br />It is important that the cause of your infection, and potentially a tuberculosis diagnosis, be confirmed before beginning treatment with this medicine, otherwise your treatment might not work properly and your condition may worsen.<br />This medicine may cause a drug reaction (DRESS syndrome) resulting in skin redness, fever, inflammation of internal organs, changes in your blood and systemic diseases.<br />If any of these symptoms occur, stop taking the medicine and contact your doctor as soon as possible. He or she will evaluate whether to stop your treatment.<br />This medicine may cause serious skin reactions. If you notice any changes to your skin (e.g. ulcers in your mouth, throat, nose, or genitals, extensive blisters or peeling), red, swollen eyes (Stevens-Johnson Syndrome - SJS), serious generalized skin damage with detachment of the epidermis and upper mucous membranes (toxic epidermal necrolysis - TEN), or red, flaky skin rash with pustules and blisters (acute generalized exanthematous pustulosis - AGEP), stop the treatment and contact your doctor as soon as possible.<br />Taking this medicine at the same time as other medicines may make them less effective. If you are taking Rifadin, always tell your doctor before taking any other medicine (see section &ldquo;Other medicines and Rifadin&rdquo;).<br />This medicine can cause a change in coloration (yellow, orange, red, brown) of the teeth, urine, sweat, phlegm, and tears, and may permanently stain soft contact lenses.<br />Laboratory tests<br />Your doctor will prescribe some blood tests before you take this medicine. In addition, your doctor will see you every month during treatment.<br />Other medicines and Rifadin<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />&bull; You should not use Rifadin if you are simultaneously taking medicines containing saquinavir/ritonavir (used to treat HIV infection), halothane (an anesthetic), or daclatasvir, simpeprevir, sofosbuvir and telaprevir (used to treat hepatitis C, a liver infection caused by a virus).<br />&bull; You should not use Rifadin at the same time as other antibiotics which cause blood clotting problems (e.g. cefazolin) as this can cause serious, sometimes fatal, blood clotting disorders, If you have to take both medicines, your doctor will monitor you, particularly for your blood.<br />In particular, tell your doctor if you are taking any of the following medicines as your dose might have to be adjusted:<br />&bull; medicines to treat seizures or epilepsy (for example phenytoin);<br />&bull; medicines to control heartbeat problems (for example disopyramide, mexiletine, quinidine, propafenone, tocainide);<br />&bull; medicines to treat some types of cancer (for example tamoxifen, toremifene, irinotecan);<br />&bull; medicines to treat depression and other nervous system disorders (for example nortriptyline, haloperidol);<br />&bull; medicines to prevent blood clots (for example warfarin);</p><p>&bull; medicines to treat fungal infections (for example fluconazole, itraconazole, ketoconazole);<br />&bull; medicines to treat HIV infections (for example zidovudine, saquinavir, indinavir, efavirenz);<br />&bull; medicines to treat anxiety and sleep disorders (for example zopiclone, zolpidem, benzodiazepines in general, such as diazepam, barbiturates);<br />&bull; medicines to treat high blood pressure or other heart problems (for example enalapril, losartan, diltiazem, nifedipine, verapamil and cardiac glycosides and medicines known as beta-blockers);<br />&bull; antibiotics (for example fluoroquinolones such as telithromycin, quinine, dapsone, doxycycline, chloramphenicol, clarithromycin);<br />&bull; anti-inflammatory medicines, such as cortisone;<br />&bull; medicines to lower cholesterol (for example clofibrate, statins);<br />&bull; medicines containing hormones (for example gestrinone, oral contraceptives such as the pill, estrogens and progestogens);<br />&bull; medicines to lower the body&rsquo;s immune response (for example tacrolimus, ciclosporin);<br />&bull; medicines to treat diabetes (for example sulfonylureas, thiazolidinediones in general, such as rosiglitazone);<br />&bull; a thyroid medicine (levothyroxine);<br />&bull; drugs used to treat pain (for example oxycodone, morphine) or to treat drug addiction (for example methadone);<br />&bull; medicines to treat parasitic infections (for example praziquantel, atovaquone);<br />&bull; a medicine used in amyotrophic lateral sclerosis (riluzole);<br />&bull; medicines to treat nausea and vomiting, such as ondansetron;<br />&bull; a medicine to treat breathing disorders (theophylline).<br />Take special care if you are taking:<br />&bull; antacids: take Rifadin at least 1 hour before taking antacids;<br />&bull; oral contraceptives: to avoid an unwanted pregnancy, you should switch to a different type of contraception, using a reliable barrier method such as condoms or an IUD (intrauterine device), as Rifadin makes the contraceptive pill less effective;<br />&bull; isoniazid: use in combination with rifampicin may increase the risk of liver problems, for which your doctor may order periodic blood tests;<br />&bull; para-aminosalicylic acid and Rifadin must be taken at an interval of at least 8 hours (para-aminosalicylic acid is an antibiotic).<br />Diagnostic tests<br />Rifadin may affect the results of some diagnostic and laboratory tests. Tell your doctor if you are having any medical or laboratory tests, particularly:<br />&bull; tests to measure vitamin B12 or folate concentrations in the blood;<br />&bull; gallbladder tests;<br />&bull; urine tests to determine the presence of opiates.<br />Increased values in certain liver function tests, such as bilirubin and transaminases, may be detected, particularly in the first few days of treatment. Your doctor will decide whether these need to be checked.<br />Pregnancy, breast-feeding and fertility<br />If you are pregnant, think you may be pregnant or are planning to have a baby or if you are breast-feeding, you should only use this medicine if your doctor considers it necessary and you are under medical supervision.<br />Driving and using machines<br />Rifadin may cause some undesirable effects (such as dizziness, drop in blood pressure, headache) which may reduce your ability to concentrate and perform certain activities that require attention. If this happens to you, do not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has instructed you. Check with your doctor or pharmacist if you are not sure.<br />Adults<br />Treatment of tuberculosis<br />The recommended dose taken once daily is:<br />- for patients weighing more than 50 kg: 600 mg per day;<br />- for patients weighing less than 50 kg: 450 mg per day.<br />Treatment of infections other than tuberculosis<br />The recommended dose may be increased to 900 - 1200 mg, divided into two daily doses.<br />Use in children<br />The recommended dose is 10 mg - 20 mg per kg body weight divided into two equal daily doses.<br />The daily dose must not exceed 600 mg.<br />How to use<br />Rifadin must be taken on an empty stomach, without food, at least 30 minutes before or 2 hours after a meal.<br />For the first three months of treatment, your doctor may have you take Rifadin along with two other drugs for tuberculosis, including isoniazid, which may be continued along with rifampicin for the entire length of your treatment. Treatment normally continues for 9 months.<br />If you take more Rifadin than you should<br />If you take more than the prescribed dose of Rifadin, contact your doctor immediately or go to the nearest hospital. Take the medicine pack with you. This is so the doctor knows what you have taken.<br />Some of the symptoms of overdose may be: nausea, vomiting, stomach pain, hives, headache, sleepiness, loss of consciousness (in the event of serious liver disease), generally temporary increase in bilirubin and other liver test results (hepatic enzymes). Other symptoms include: reddish-brown or orange coloration of skin, urine, sweat, saliva, tears and stools; the intensity of the color is proportional to the dose taken. Children may experience swollen face, eyes or eyelids. More rarely, the following may occur: drop in blood pressure, fast and/or uneven heartbeat, seizures, and cardiac arrest.<br />If you forget to take Rifadin<br />Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Rifadin<br />Do not stop taking your treatment without talking to a doctor, as suddenly stopping treatment can cause allergic reactions (anaphylactic shock); see section 4.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you develop any of the following side effects, stop taking the medicine and immediately tell your doctor:<br />&bull; skin problems, swallowing or breathing problems, shortness of breath, swelling of the lips, face, throat or tongue. These may be symptoms of anaphylactic shock (a serious allergic reaction);<br />&bull; skin changes (e.g. ulcers in your mouth, throat, nose or genitals, extensive blistering or peeling), conjunctivitis (red, swollen eyes). These may be symptoms of a serious skin reaction called &ldquo;Stevens-Johnson Syndrome&rdquo; &ndash; SJS;</p><p>&bull; serious generalized skin damage (detachment of the epidermis and upper mucous membranes) (toxic epidermal necrolysis &ndash; TEN);<br />&bull; red, flaky skin rash with pustules and blisters (acute generalized exanthematous pustulosis):<br />&bull; a drug reaction resulting in skin redness, fever, inflammation of internal organs, changes in your blood and systemic diseases (DRESS syndrome);<br />&bull; inflammation of the small blood vessels of the skin which leads to a purplish-red rash, called &ldquo;purpura&rdquo;. The medicine may cause a reduction in the number of certain blood cells called platelets (thrombocytopenia, which may affect up to 1 in 10 patients), which can lead to this abnormal collection of blood under the skin. This condition generally resolves when treatment is stopped. However, it can also worsen, causing bleeding in the brain and death if treatment is not stopped or if it is resumed after the development of &ldquo;purpura&rdquo;.<br />The following side effects have also been reported with the use of this medicine:<br />Very common side effects (may affect more than 1 in 10 patients):<br />&bull; fever, chills.<br />Common side effects (may affect up to 1 in 10 patients):<br />&bull; headache, dizziness;<br />&bull; nausea, vomiting;<br />&bull; increase in blood bilirubin (hyperbilirubinemia);<br />&bull; changes in certain liver function test results (increase in aspartate aminotransferase; increase in alanine aminotransferase).<br />Uncommon side effects (may affect up to 1 in 100 patients):<br />&bull; certain blood changes (leucopenia);<br />&bull; diarrhea.<br />Side effects of unknown frequency:<br />&bull; painful inflammation of the colon (the last part of the intestine) involving cramps, continuous diarrhea, weakness and fever (pseudomembranous colitis);<br />&bull; certain blood changes (agranulocytosis, eosinophilia, leukopenia, anemia);<br />&bull; blood clotting disorders (vitamin K dependent);<br />&bull; bleeding;<br />&bull; inflammation of the liver (hepatitis);<br />&bull; decreased appetite (anorexia);<br />&bull; stomach and intestinal disorders, abdominal discomfort;<br />&bull; redness and other skin disorders, with pruritus, hives;<br />&bull; muscle weakness, muscle diseases (myopathies);<br />&bull; bleeding after birth (in both mother and fetus);<br />&bull; menstrual cycle disorders;<br />&bull; fluid retention with subsequent swelling (edema);<br />&bull; change in color of tears, phlegm, sweat or urine;<br />&bull; change in color of the teeth (which can be permanent);<br />&bull; porphyria attacks in patients already affected by this disease (a rare hereditary blood metabolism disorder);<br />&bull; changes in certain liver function test results (increase in hepatic enzymes, increase in alkaline phosphatase);<br />&bull; increased blood creatinine levels (creatinine indicates the level of kidney function);<br />&bull; flu with bone pain and general discomfort;<br />&bull; breathing difficulties (dyspnea) and wheezing;<br />&bull; drop in blood pressure;<br />&bull; drop in blood pressure with resulting impairment of consciousness and other mental faculties (shock);<br />&bull; flushing;<br />&bull; acute kidney damage due to development of kidney diseases (e.g. renal tubular necrosis or tubulointerstitial nephritis);<br />&bull; a rare condition that affects the skin and mucous membranes involving the development of blisters on the skin (pemphigus);<br />&bull; a serious disease involving the formation of diffuse blood clots (disseminated intravascular coagulation);<br />&bull; mental disorders;<br />&bull; impaired adrenal function in patients who already have adrenal problems;<br />&bull; inflammation of the blood vessels causing skin problems, weakness, fever, joint and muscle pains (vasculitis).<br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEEP THIS MEDICINE OUT OF THE SIGHT AND REACH OF CHILDREN.<br />Do not store above 30&deg;C.<br />Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Rifadin contains<br />Rifadin 150 mg hard capsules and Rifadin 300 mg hard capsules<br />&bull; The active substance is rifampicin. One hard capsule contains 150 mg or 300 mg of rifampicin.<br />&bull; The other ingredients are: maize starch, magnesium stearate, gelatin, erythrosine (E 127), indigo carmine (E 132), titanium dioxide (E 171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rifadin hard capsules are supplied in boxes of:
• 8 capsules,
• 100 Capsules
• 100 capsules in amber glass bottles.
Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Sanofi S.p.A. Viale L. Bodio, 37/B &mdash; 20158 Milan, Italy</p><p><br /><strong>Manufacturer</strong><br />Sanofi S.p.A. Via Valcanello, 4 - 03012 Anagni (FR), Italy<br />Sanofi Industries South Africa (Pty) Ltd.<br />315 Waltloo Road, Waltloo, Pretoria, South Africa</p><p><br /><strong>Secondary Packager</strong><br />Sanofi Aventis Arabia Co. Ltd,<br />Industrial Valley Phase 1A St. KAEC,,<br />King Abdullah Economic City, KAEC<br />Rabigh, 21423, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ريفادين على الريفامبيسين وهو مضاد حيوي يمكنه قتل أنواع متعددة من البكتيريا المؤذية، بخاصة تلك التي تسبّب<br />مرض السلّ وهو مرض معدٍ يصيب الرئتين عادة.<br />يمكن استعمال ريفادين مع مضادات حيويّة أخرى أو مع أدوية أخرى مثل أدوية العلاج الكيميائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستعمل ريفادين<br />- إذا كنت مصابًا بحساسيّة ضدّ المادة الفاعلة أو ضدّ أيّ من مكوّنات هذا الدواء الأخرى المذكورة في القسم 6 ؛<br />- إذا كنت مصابًا بحالة تسبّب اصفرار الجلد والعينين )يرقان(؛<br />- إذا كنت تأخذ دواء يحتوي على ساكينافير أو ريتونافير وهما دواءان يُستعملان لعلاج عدوى فيروس نقص المناعة<br />البشرية، الفيروس الذي يسبّب مرض السيدا )راجع فقرة &quot;أدوية أخرى وريفادين&quot;(.<br />تحذيرات واحتياطات<br />تحدّث إلى طبيبك أو إلى الصيدلي قبل أخذ ريفادين إذا :<br />- كنت تعاني من مشاكل في الكبد؛<br />- كنت مصابًا بالبورفيريا )اضطراب وراثيّ نادر في أيض الدم( ؛<br />- كنت تعاني من سوء التغذية أو كنت متقدّمًا في السن، أو إذا كان طفل صغير سيأخذ الدواء، بخاصة إذا كان مضاد<br />حيويّ آخر يُسمّى إيزونيازيد يُؤخذ في الوقت عينه ؛<br />- كنت تعاني من اضطرابات في النزيف أو كنت تُصاب بآثار كدمات بسهولة )لأنّ هذا الدواء يمكن أن يسبّب<br />اضطرابات في تخثّر الدم( ؛<br />- كنت تأخذ مضادات حيويّة أخرى )لأنّ مضادات حيويّة معيّنة يمكنها أن تزيد خطر اضطرابات تخثّر الدم(.<br />إذا لم تكن متأكّدًا مما إذا كانت إحدى الحالات أعلاه تنطبق عليك، تحدّث إلى الطبيب أو الصيدليّ قبل أخذ ريفادين.<br />من المهمّ تأكيد سبب العدوى التي تصيبك والتشخيص المحتمل لمرض السلّ قبل البدء بالعلاج بهذا الدواء، وإلاّ قد لا يعمل<br />علاجك بشكل صحيح وقد تزداد حالتك سوءًا.</p><p>يمكن أن يسبّب هذا الدواء ارتكاسًا دوائيًا )متلازمة الطفح الدوائي مع فرط حمضات وأعراض جهازيّة DRESS ( يسبّب<br />احمرار الجلد وحمى والتهاب الأعضاء الداخليّة وتغييرات في الدم وأمراضًا جهازيّة.<br />في حال حصول أيّ عارض من هذه العوارض، توقّف عن أخذ الدواء واتصل بطبيبك في أسرع وقت ممكن. فسوف يقيّم<br />ضرورة إيقاف علاجك.<br />يمكن أن يسبّب هذا الدواء ارتكاسات جلديّة خطيرة. إذا لاحظت أيّ تغييرات في جلدك )مثلاً تقرّحات في فمك أو حلقك أو<br />أعضائك التناسليّة، أو بثور منتشرة أو تقشّر( أو إذا أصبت باحمرار أو تورّم في العينين )متلازمة ستيفنز-جونسون( أو<br />بضرر جلديّ خطير ومعمّم مع انقلاع البشرة والأغشية المخاطيّة العليا )النكروز الجلدي السام( أو طفح جلدي قشاري<br />أحمر مع بثور )البُثار الطفحي الحاد المعمّم(، أوقف العلاج واتصل بطبيبك في أسرع وقت ممكن.<br />إنّ أخذ هذا الدواء في الوقت ذاته مع أدوية أخرى قد يجعلها أقلّ فعاليّة. إذا كنت تأخذ ريفادين، أعلم طبيبك دائمًا قبل أخذ أيّ<br />دواء آخر )راجع فقرة &quot;أدوية أخرى وريفادين&quot;(.<br />يمكن أن يسبّب هذا الدواء تغييرًا في لون )أصفر، برتقاليّ، أحمر، بنّي( الأسنان والبول والعرق والبلغم والدموع وقد يلطّخ<br />العدسات اللاصقة الطريّة بشكل دائم.<br />الفحوصات المخبريّة<br />سوف يصف طبيبك بعض فحوصات الدم قبل أخذ هذا الدواء. بالإضافة إلى ذلك، سوف يراك طبيبك كلّ شهر في خلال مدّة<br />العلاج.<br />أدوية أخرى وريفادين<br />أعلم الطبيب أو الصيدلي إذا كنت تأخذ أو إذا أخذت مؤخّرًا أو قد تأخذ أيّ أدوية أخرى.<br />- لا ينبغي بك استعمال ريفادين إذا كنت تأخذ في الوقت ذاته أدوية تحتوي على ساكينافير/ريتونافير )دواءان يُستعملان<br />لعلاج عدوى فيروس نقص المناعة البشريّة(، هالوثان )مخدّر( أو داكلاتاسفير، سيمبيبريفير، سوفوسبوفير وتيلابريفير<br />)أدوية تُستعمل لعلاج التهاب الكبد الوبائي سي، عدوى في الكبد يسبّبها فيروس(.<br />- لا ينبغي بك استعمال ريفادين في الوقت ذاته مع مضادات حيويّة أخرى تسبّب مشاكل في تخثّر الدم )مثلاً سيفازولين(<br />لأنّ هذا يمكن أن يسبّب اضطرابات خطيرة وقاتلة أحيانًا في تخثّر الدم. وإذا كان عليك أخذ الدوائين، فسوف يراقبك<br />طبيبك، وبخاصة دمك.<br />بشكل خاص، أعلم طبيبك إذا كنت تأخذ أيّ دواء من الأدوية التالية لأنّه قد يكون من الضروريّ تعديل جرعتك:<br />- أدوية علاج الاختلاجات أو الصرع )مثلاً فينيتوين(؛<br />- أدوية التحكّم بمشاكل ضربات القلب )مثلاً ديزوبيراميد، ميكسيليتين، كينيدين، بروبافينون، توكاينيد(؛<br />- أدوية علاج بعض أنواع السرطان )مثلاً تاموكسيفين، توريميفين، إيرينوتيكان(؛<br />- أدوية علاج الاكتئاب واضطرابات أخرى في الجهاز العصبي )مثلاً نورتريبتيلين، هالوبيريدول(؛<br />- أدوية منع تخثّر الدم )مثلاً وارفارين(؛<br />- أدوية علاج حالات العدوى الفطريّة )فلوكونازول، إتراكونازول، كيتوكونازول(؛<br />- أدوية علاج عدوى فيروس نقص المناعة البشرية )مثلاً زيدوفودين، ساكينافير، إندينافير، إيفافيرنز(؛<br />- أدوية علاج القلق واضطرابات النوم )مثلاً زوبيكلون، زولبيديم، أدوية البنزوديازيبين بشكل عام، مثل ديازيبام،<br />الباربيتورات(؛<br />- أدوية علاج ضغط الدم المرتفع أو مشاكل قلبيّة أخرى )مثلاً إينالابريل، لوزارتان، ديلتيازيم، نيفيديبين، فيراباميل<br />والغليكوسيدات القلبيّة والأدوية المعروفة بحاصرات بيتا(؛<br />- المضادات الحيويّة )مثلاً الفلوروكينولونات مثل تيليثرومايسين، كينين، دابسون، دوكسيسيكلين، كلورامفينيكول،<br />كلاريثرومايسين(؛<br />- مضادات الالتهاب، مثل الكورتيزون؛<br />- الأدوية المخفّضة للكوليستيرول )مثلاً كلوفبرات، أدوية الستاتين(؛<br />- الأدوية التي تحتوي على هورمونات )مثلاً جسترينون، وسائل منع الحمل عن طريق الفم مثل حبوب منع الحمل<br />والإستروجين والبروجستيرون(؛<br />- الأدوية المخفّضة لاستجابة الجسم المناعية )مثلاً تاكروليموس، سيكلوسبورين(؛<br />- أدوية علاج داء السكّري )مثلاً السلفونيل يوريا، الثيازوليدينيديونات بشكل عام، مثل روزيغليتازون(؛<br />- دواء للغدّة الدرقيّة )ليفوثيروكسين(؛<br />- الأدوية المستعملة لعلاج الألم )مثلاً أوكسيكودون، مورفين( أو لعلاج الإدمان على المخدّرات )مثلاً ميثادون(؛<br />- أدوية علاج الالتهابات الطفيلية )مثلاً برازيكوانتيل، أتوفاكون(؛<br />- دواء يُستعمل في التص لّب الجانبي الضموري )ريلوزول(؛</p><p>الأدوية المستعملة لعلاج الغثيان والتقيّؤ مثل أوندانسيترون؛<br />- دواء يُستعمل لعلاج اضطرابات التنفّس )ثيوفيلين(.<br />إعتمد عناية خاصة إذا كنت تأخذ:<br />- مضادات حموضة: خذ ريفادين قبل ساعة على الأقلّ من أخذ مضادات الحموضة ؛<br />- وسائل منع الحمل عن طريق الفم: لتفادي الحمل غير المرغوب به، يجب أن تعتمدي نوعًا مختلفًا من منع الحمل،<br />باستعمال وسيلة حاجزة موثوق بها مثل الواقيات الذكريّة أو مانعة الحمل الرحميّة، لأنّ ريفادين يُضعف فعاليّة حبوب<br />منع الحمل؛<br />- إزونيازيد: إنّ استعماله بالاشتراك مع الريفامبيسين قد يزيد خطر مشاكل الكبد التي يمكن أن يطلب طبيبك من أجلها<br />فحوصات دم دوريّة ؛<br />- يجب أخذ حمض البارا-أمينوساليسيليك وريفادين حسب فاصل وقت من 8 ساعات على الأقلّ )حمض البارا -<br />أمينوساليسيليك هو مضاد حيوي(.<br />الاختبارات التشخيصيّة<br />يمكن أن يؤثّر ريفادين على نتائج بعض الاختبارات التشخيصيّة والمخبريّة. أعلم طبيبك إذا كنت تُجري أيّ اختبارات طبيّة<br />أو مخبريّة، بشكل خاص:<br />- اختبارات لقياس تركيزات الفيتامين ب 12 أو الفولات في الدم ؛<br />- اختبارات المرارة؛<br />- اختبارات بول لتحديد وجود مواد أفيونيّة.<br />يمكن كشف قيم مرتفعة في بعض فحوصات وظيفة الكبد، مثل البيليروبين وناقلات الأمين، بخاصة في خلال الأيّام القليلة<br />الأولى من العلاج. سوف يقرّر طبيبك ما إذا كان من الضروري التحقق من هذه القيم.<br />الحمل والإرضاع والخصوبة<br />إذا كنتِ حاملاً أو كنتِ تعتقدين نفسك حاملاً أو كنتِ تنوين الحمل أو إذا كنت مرضعة، يجب أن تستعملي هذا الدواء فقط إذا<br />اعتبر طببيك استعماله ضروريًا وكنتِ تخضعين لإشراف طبّي.<br />قيادة السيّارات واستعمال الآلات<br />يمكن أن يسبّب ريفادين بعض التأثيرات غير المرغوب بها )مثل الدوار وانخفاض ضغط الدم والصداع( مما قد يحدّ من<br />قدرتك على التركيز وعلى القيام ببعض النشاطات التي تتطلّب انتباهًا. إذا حصل هذا لك، لا تقد سيّارة أو تستعمل آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ هذا الدواء دائمًا حسب تعليمات طبيبك أو الصيدليّ تمامًا. إسأل طبيبك أو الصيدلي إذا لم تكن متأكّدًا.<br />البالغون<br />علاج مرض الس ل<br />تبلغ الجرعة الموصى بها التي تُؤخذ مرّة في اليوم :<br />- للمرضى الذين يزنون أكثر من 50 كلغ: 600 ملغ في اليوم ؛<br />- للمرضى الذين يزنون أقلّ من 50 كلغ: 450 ملغ في اليوم.<br />علاج حالات عدوى غير مرض الس ل<br />يمكن زيادة الجرعة الموصى بها إلى 900 - 1200 ملغ، تُقسم إلى جرعتين يوميّتين.<br />الاستعمال لدى الأطفال<br />تبلغ الجرعة الموصى بها 10 ملغ- 20 ملغ لكلّ كيلو من وزن الجسم وتُقسم إلى جرعتين يوميّتين متساويتين. لا ينبغي أن<br />تتخطّى الجرعة اليوميّة 600 ملغ.</p><p>كيفيّة الاستعمال<br />يجب أخذ ريفادين على معدة فارغة، بدون أيّ طعام، قبل 30 دقيقة أو بعد ساعتين من الطعام على الأقلّ.<br />في خلال الأشهر الثلاثة الأولى من العلاج، قد يطلب منك طبيبك أخذ ريفادين مع دوائين آخرين لمرض السلّ، بما فيهما<br />إيزونيازيد، ويمكن أخذهما بالاشتراك مع الريفامبيسين طيلة مدّة علاجك. عادة ما يستمرّ العلاج لتسعة أشهر.<br />إذا أخذت كميّة ريفادين أكثر مما يجب<br />إذا أخذت جرعة من ريفادين أكثر من الجرعة الموصوفة، اتصل بطبيبك على الفور أو اذهب إلى قسم الطوارئ في المستشفى<br />الأقرب. خذ علبة الدواء معك لكي يعرف الطبيب ماذا أخذت.<br />قد تكون بعض عوارض فرط الجرعة ما يلي: غثيان، تقيّؤ، ألم في المعدة، شرى، صداع، نعاس، فقدان الوعي )في حالة<br />مرض الكبد الخطير(، ارتفاع مؤقّت بصورة عامة في البيليروبين وفي نتائج فحوصات الكبد الأخرى )أنزيمات الكبد(.<br />تتضمّن العوارض الأخرى: تلوّن البشرة والبول والعرق واللعاب والدموع والبراز بلون محمرّ بنّي أو برتقاليّ؛ شدّة اللون<br />تتناسب مع الجرعة المأخوذة. قد يُصاب الأطفال بتورّم الوجه أو العينين أو الجفنين. بصورة نادرة أكثر يمكن أن يحصل ما<br />يلي: انخفاض في ضغط الدم، سرعة و/أو عدم انتظام ضربات القلب، نوبات صرع، وتوقّف القلب.<br />إذا نسيت أخذ ريفادين<br />لا تأخذ جرعة مضاعفة للتعويض عن جرعة نسيت أخذها.<br />إذا توقّفت عن أخذ ريفادين<br />لا تتوقّف عن أخذ علاجك بدون التحدّث إلى طبيب، لأنّ الإيقاف المفاجئ للعلاج يمكن أن يسبّب ارتكاسات تحسسيّة<br />)صدمة الحساسية(؛ راجع الفقرة 4 .<br />إذا كان لديك أسئلة إضافيّة حول استعمال هذا لدواء، إطرحها على طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدوية كلّها، يمكن أن يسبّب هذا الدواء تأثيرات جانبيّة لا تُصيب المرضى كلّهم.<br />إذ أصبت بأيّ من التأثيرات الجانبيّة التالية، توقّف عن أخذ الدواء وأعلم طبيبك على الفور:<br />- مشاكل جلديّة، مشاكل في البلع أو التنفّس، ضيق نفس، تورّم الشفتين أو الوجه أو اللسان. قد تكون هذه عوارض صدمة<br />الحساسية )ارتكاس تحسسي خطير(؛<br />- تغييرات جلديّة )مثلاً تقرّحات في الفم أو الحلق أو الأنف أو الأعضاء التناسليّة، بثور واسعة النطاق أو تقشّر(، التهاب<br />الملتحمة )احمرار العينين وتورّهما(. قد تكون هذه عوارض ارتكاس جلدي خطير يُسمّى &quot;متلازمة ستيفنز-جونسون&quot;؛<br />- ضرر جلديّ عام وخطير )إنقلاع البشرة والأغشية المخاطيّة العليا( )النكروز الجلدي السام(؛<br />- طفح جلدي قشاري أحمر مع بثور )البُثار الطفحي الحاد المعمّم(؛<br />- ارتكاس دوائي يسبّب احمرار البشرة وحمى والتهاب الأعضاء الداخليّة وتغييرات في دمك وأمراضً ا جهازيّة<br />)متلازمة الطفح الدوائي مع فرط حمضات وأعراض جهازيّة DRESS ؛)<br />- التهاب الأوعية الدمويّة الصغيرة في الجلد مما يسبّب طفحًا أحمر أرجوانيًا، يسمّى &quot;فرفريّة&quot;. يمكن أن يسبّب الدواء<br />انخفاضًا في عدد بعض خلايا الدم تُسمّى صفيحات )قلّة الصفيحات التي قد تصيب لغاية مريض واحد من أصل 10<br />مرضى(، مما يمكن أن يؤدّي إلى التجمّع غير العادي هذا للدم تحت الجلد. عادة ما تختفي هذه الحالة عند إيقاف العلاج.<br />ولكن يمكن أن تزداد سوءًا أيضًا، وتسبب نزيفًا في الدماغ والوفاة إذا لم يتمّ إيقاف العلاج أو إذا استُؤنف بعد حصول<br />&quot;الفرفريّة&quot;.<br />تمّت الإفادة أيضًا عن التأثيرات الجانبيّة التالية مع استعمال هذا الدواء:<br />تأثيرات جانبيّة شائعة جدًا )قد تُصيب أكثر من مريض من أصل 10 مرضى(:<br />- حمى، قشعريرات.<br />تأثيرات جانبيّة شائعة )قد تُصيب لغاية مريض من أصل 10 مرضى(:<br />- صداع، دوار ؛<br />- غثيان، تقيّؤ؛<br />- ارتفاع في بيليروبين الدم )فرط بيليروبين الدم(؛<br />- تغييرات في نتائج بعض فحوصات وظيفة الكبد )ارتفاع في ناقلة أمين الأسبارتات؛ ارتفاع في ناقلة أمين الألانين(.<br />تأثيرات جانبيّة غير شائعة )قد تُصيب لغاية مريض من أصل 100 مريض(:<br />- بعض تغييرات الدم )نقص الكريات البيض(؛</p><p>إسهال.<br />تأثيرات جانبيّة غير معروفة معدّل الحصول :<br />- التهاب مؤلم في القولون )الجزء الأخير من الأمعاء( يشمل تشنّجات وإسهالاً مستمرًّا، وضعفًا وحمى )التهاب القولون<br />الغشائي الكاذب(؛<br />- بعض التغييرات في الدم )ندرة المحببات ، فرط الحمضات ، قلة الكريات البيض، فقر دم(؛<br />- اضطرابات في تخثّر الدم )تعتمد على الفيتامين كاي(؛<br />- نزيف؛<br />- التهاب الكبد؛<br />- انخفاض الشهيّة )فقدان الشهيّة( ؛<br />- اضطرابات في المعدة والأمعاء؛ انزعاج في البطن ؛<br />- احمرار أو اضطربات جلديّة أخرى، مع حكّة، شرى؛<br />- ضعف عضلي، أمراض عضليّة )اعتلالات عضليّة(؛<br />- نزيف بعد الولادة )لدى الأم والطفل(؛<br />- اضطرابات في الدورة الشهريّة ؛<br />- احتباس السوائل مع تورّم لاحق )أوديما(؛<br />- تغيير في لون الدموع أو البلغم أو العرق أو البول ؛<br />- تغيير في لون الأسنان )يمكن أن يكون دائمًا(؛<br />- نوبات بورفيريا لدى المرضى المصابين بهذا المرض )اضطراب وراثيّ نادر في أيض الدم(؛<br />- تغييرات في بعض نتائج فحص وظيفة الكبد )ارتفاع في انزيمات الكبد، ارتفاع في فوسفاتاز الألكالاين(؛<br />- ارتفاع مستويات كرياتينين الدم )يشير الكرياتينين إلى مستوى الوظيفة الكلويّة(؛<br />- زكام مع وجع في العظام وانزعاج عام؛<br />- صعوبات في التنفّس )ضيق تنفّس( وأزيز؛<br />- هبوط في ضغط الدم ؛<br />- هبوط في ضغط الدم مع ضعف الوعي وقدرات عقليّة أخرى )صدمة(؛<br />- تورّد؛<br />- ضرر كلوي حاد بسبب حصول أمراض كلويّة )مثلاً النكروز النبيبي الكلوي أو التهاب الكلية الأنبوبي الخلالي( ؛<br />- حالة نادرة تصيب الجلد والأغشية المخاطيّة تشمل ظهور بثور على الجلد )فقاع(؛<br />- مرض خطير يشمل تشكّل خثرات دم منتشرة )التخثر المنتثر داخل الأوعية(؛<br />- اضطرابات عقليّة ؛<br />- ضعف وظيفة الغدّة الكظريّة لدى المرضى الذين لديهم أصلاً مشاكل في الغدّة الكظريّة ؛<br />- التهاب الأوعية الدمويّة مما يسبّب مشاكل في الجلد وضعفًا وحمى وأوجاعًا في المفاصل والعضلات )التهاب الأوعية<br />الدمويّة(.<br /><strong>للإبلاغ عن أي أعراض جانبية :<br />&bull; المملكة العربية السعودية :<br />- المركز الوطني للتيقظ والسلامة الدوائية<br />&bull; الرقم المُوحّد للهيئة العامّة للغذاء والدّواء: 19999<br />&bull; البريد الالكتروني: npc.drug@sfda.gov.sa<br />&bull; الموقع الالكتروني: https://ade.sfda.gov.sa<br />&bull; سانوفي للتيقظ الدوائي: KSA_Pharmacovigilance@sanofi.com</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ في درجة حرارة لا تتجاوز 30 درجة مئويّة.<br />يُحفظ هذا الدواء بعيدًا عن نظر الأطفال ومتناولهم.<br />لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحيّة المدوّن على علبة الكرتون والظرف بعد كلمة EXP . يشير تاريخ انتهاء<br />الصلاحيّة إلى اليوم الأخير من الشهر المذكور.<br />لا تقم برمي أيّ أدوية في مياه الصرف الصحّي أو مع النفايات المنزليّة. إسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي<br />لم تعد تستعملها، فمن شأن هذه الإجراءات المساعدة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا يحتوي ريفادين<br />ريفادين 150 ملغ، كبسولات صلبة وريفادين 300 ملغ، كبسولات صلبة<br />- المادة الفاعلة هي ريفامبيسين. تحتوي الكبسولة الصلبة الواحدة على 150 ملغ أو 300 ملغ من الريفامبيسين.<br />- المكوّنات الأخرى هي: نشا الذرة، ستيارات المغنيزيوم، هلام، إيريثروزاين )إي 127 (، قرمز نيلي )إي 132 (، ثاني<br />أكسيد التيتانيوم )إي 171</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">كيف هو شكل ريفادين ومحتويات العلبة<br />كبسولات ريفادين الصلبة تأتي في علب من 8 أو 100 كبسولات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسويق</strong><br />Sanofi S.p.A. &mdash; Viale L. Bodio, 37/B &mdash; 20158 Milan, Italy</p><p><br /><strong>المصنّع</strong><br />Sanofi S.p.A. &ndash; Via Valcanello, 4 - 03012 Anagni (FR), Italy<br />Sanofi Industries South Africa (Pty) Ltd.<br />315 Waltloo Road, Waltloo, Pretoria, South Africa</p><p><br /><strong>التغليف الثانوي</strong><br />Sanofi Aventis Arabia Co. Ltd,<br />Industrial Valley Phase 1A St. KAEC,, King Abdullah Economic City, KAEC<br />Rabigh, 21423, Saudi Arabia</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rifadin 150 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rifadin 150 mg hard capsules
One capsule contains 150 mg of rifampicin.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules, coated tablets, syrup, powder and solvent for solution for infusion.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Infections caused by rifampicin-susceptible microorganisms, particularly Mycobacterium tuberculosis and other mycobacteria. In mycobacterial infections, this medicinal product should be used in conjunction with other antibiotics or specific chemotherapeutic agents. For infections other than tuberculosis, concomitant administration of another active antibiotic is recommended to prevent development of resistance. The susceptibility of pathogens, or their possible primary or acquired resistance, should be determined by means of an antibiotic susceptibility test, as is generally required for the appropriate use of antibiotics.<br />If the infection does not respond to treatment within a reasonable period of time, treatment should be changed, and if relapse occurs, administration of rifampicin is advised only after carrying out preliminary bacteriological tests.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Oral Rifadin</strong><br />Posology<br />Adults: in the treatment of tuberculosis, 600 mg daily as a single dose in patients weighing more than 50 kg (450 mg in patients weighing less than 50 kg), in conjunction with other antituberculosis drugs. For other infections, the daily dose may reach 900-1200 mg, and is usually divided into two doses.<br />Pediatric population: the recommended daily dose is 10-20 mg/kg body weight divided into two equal doses. A daily dose of 600 mg should not be exceeded.</p><p>The bottle must be shaken well but gently in order to avoid foaming.<br />The measuring cup should be rinsed thoroughly with water after measuring out the syrup.<br />Method of administration<br />For faster and more complete absorption, Rifadin should be taken on an empty stomach and not at meal times (at least 30 minutes before a meal or 2 hours after a meal).<br />In newly confirmed cases, treatment is most effective when continuous and administered for a short time, i.e. 9 months, at the doses given above, in combination with isoniazid and, for the first 3 months, a third antituberculosis agent.<br />Rifadin solution for infusion<br />Posology<br />Dose in non-specific infections: the recommended daily dose for adults is 600 mg (as determined by the doctor: one 600 mg vial daily).<br />Dose in pulmonary tuberculosis: the recommended daily dose for adults is 600 mg, generally as a single dose. The treatment of pulmonary tuberculosis with Rifadin for infusion should provide for the concomitant use of other antituberculosis drugs.<br />Method of administration<br />Rifadin is available in a vial (containing 600 mg of antibiotic) with a solvent ampoule. Rifadin for intravenous infusion is particularly recommended when oral administration of the antibiotic is not possible or not recommended due to the clinical status of the patient (surgical procedures, impaired gastrointestinal absorption etc.) or due to gastric intolerance.<br />The solution is prepared by adding the solvent from the ampoule included in the pack to the vial of rifampicin and shaking vigorously and continuously for about 30 seconds.<br />As soon as the foam has completely disappeared, the solution should be diluted in 500 mL of 5% glucose solution or normal saline. Prepared solutions should be used within a few hours (see section 6.3). The drip rate should be adjusted so that the infusion lasts for about 3 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Rifadin must not be administered in case of jaundice.
Rifadin use is contraindicated when given concurrently with the combination of saquinavir/ritonavir (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rifadin must not be used for the treatment of non-tubercular infections if an associated tubercular form is suspected, until the diagnosis has been confirmed, so as not to mask the tubercular process or cause mycobacterial resistance.<br />Special caution must be exercised in malnourished elderly subjects and in young children, particularly when isoniazid is coadministered.<br />Liver<br />Patients with impaired liver function should only be given Rifadin in cases of necessity and then with caution and under strict medical supervision. In these patients, careful monitoring of liver function, especially serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) should be carried out prior to therapy and then every 2 to 4 weeks during therapy. If signs of hepatocellular damage occur, Rifadin should be discontinued.<br />In some cases, hyperbilirubinemia resulting from competition between Rifadin and bilirubin for excretory pathways of hepatocytes can occur in the early days of treatment. An isolated report showing a moderate rise in bilirubin and/or transaminase level is not in itself an indication for interrupting treatment; rather, the decision should be made after repeating the tests, noting trends in the levels and considering them in conjunction with the patient&#39;s clinical condition.</p><p>Immunological reactions/anaphylaxis<br />Because of the possibility of immunological reactions including anaphylaxis occurring with intermittent therapy (less than 2 to 3 times per week) patients should be closely monitored. Patients should be cautioned against interruption of dosage regimens since these reactions may occur.<br />Severe systemic hypersensitivity reactions<br />Severe, systemic hypersensitivity reactions, including fatal cases, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome have been observed during treatment with antituberculosis therapy (see section 4.8). It is important to note that early manifestations of hypersensitivity, such as fever, lymphadenopathy or biological abnormalities (including eosinophilia, liver abnormalities) may be present even though rash is not evident. If such signs or symptoms are present, the patient should be advised to consult immediately their physician.<br />Rifadin should be discontinued if an alternative etiology for the signs and symptoms cannot be established.<br />Severe bullous reactions<br />Cases of severe bullous skin reactions such as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP) have been reported with rifampicin. If symptoms or signs of AGEP, SJS or TEN are present, rifampicin treatment must immediately be discontinued.<br />Rifadin syrup<br />Rifadin syrup contains:<br />- sucrose and, as such, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should not take this medicinal product. This medicinal product contains 12 g of sucrose per dose (600 mg). This should be taken into account in patients with diabetes mellitus. It may also be harmful to the teeth.<br />- sodium metabisulfite, which may cause allergic-type reactions in some sensitive patients, including anaphylactic symptoms and asthma attacks (bronchospasm) which may be life-threatening for the patient.<br />- methyl parahydroxybenzoate and propyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed).<br />Rifadin coated tablets<br />Rifadin tablets contain:<br />- lactose and, as such, patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.<br />- sucrose and, as such, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should not take this medicinal product.<br />Rifadin powder and solvent for solution for infusion contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium free&rdquo;.<br />Precautions<br />Adults treated with Rifadin should have baseline measurements of hepatic enzymes, bilirubin, serum creatinine, a complete blood count, and a platelet count. Baseline tests are unnecessary in children unless a complicating condition is known or clinically suspected.<br />Patients should be seen at least monthly during therapy and should be specifically questioned concerning symptoms associated with adverse reactions. All patients with abnormalities should have follow-up, including laboratory testing, if necessary.<br />Rifadin has enzyme induction properties that can enhance the metabolism of endogenous substrates including adrenal hormones, thyroid hormones, and vitamin D. Isolated reports have associated porphyria exacerbation with Rifadin administration as a result of induction of delta amino levulinic acid synthetase.<br />Rifadin may produce a change in color of the urine, sweat, sputum, and tears and the patient should be forewarned of this.<br />Soft contact lenses have been permanently stained.</p><p>Rifadin is a well characterized and potent inducer of drug metabolizing enzymes and transporters and might therefore decrease concomitant drug exposure and efficacy (see section 4.5). Therefore, patients should be advised not to take any other medication without medical advice.<br />Rifampicin may cause vitamin K dependent coagulopathy and severe bleeding (see section 4.8).<br />Monitoring of occurrence of coagulopathy is recommended for patients at particular bleeding risk. Supplemental vitamin K administration should be considered when appropriate (vitamin K deficiency, hypoprothrombinemia).<br />Rifadin solution in vials is for intravenous infusion only and must not be administered by the intramuscular or subcutaneous route. Avoid extravasation during injection; local irritation and inflammation due to extravascular infiltration of the infusion have been observed. If these occur, the infusion should be discontinued and restarted at another site.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions<br />When Rifadin is given concomitantly with the combination saquinavir/ritonavir, the potential for hepatotoxicity is increased. Therefore, concomitant use of Rifadin with saquinavir/ritonavir is contraindicated (see section 4.3).<br />When Rifadin is given concomitantly with either halothane or isoniazid, the potential for hepatotoxicity is increased. The concomitant use of Rifadin and halothane should be avoided. Patients receiving both Rifadin and isoniazid should be monitored closely for hepatotoxicity.<br />The concomitant use of rifampicin with other antibiotics causing vitamin K dependent coagulopathy such as cefazolin (or other cephalosporins with N-methyl-thiotetrazole side chains) should be avoided as it may lead to severe coagulation disorders, which may result in fatal outcome (especially with high doses). If this combination cannot be avoided, clinical monitoring, possibly including hemostatic monitoring, is required.<br />Effect of Rifadin on other medicinal products<br />Induction of drug metabolizing enzymes and transporters<br />Rifadin is a well characterized and potent inducer of drug metabolizing enzymes and transporters. Enzymes and transporters reported to be affected by Rifadin include cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 3A4 and UDP-glucoronlytransferases (UGT), sulfotransferases, carboxylesterases, and transporters including P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2). Most drugs are substrates for one or more of these enzyme or transporter pathways, and these pathways may be induced by Rifadin simultaneously. Therefore, Rifadin may accelerate the metabolism and reduce the activity of certain co-administered drugs, and has the potential to perpetuate clinically important drug-drug interactions against many drugs and across many drug classes. To maintain optimum therapeutic blood levels, dosage of drugs may require adjustment when starting or stopping concomitantly administered Rifadin.<br />The following table provides examples of the induction effect of rifampicin on exposure of selected drug metabolizing enzymes and transporter substrate drugs. Concomitant administration of rifampicine with the following drugs or class of drugs has demonstrated a decrease in drug or metabolite exposure.<br />ANTIMICROBIALS<br />Antiviral drugs<br />Antiretroviral drugs (e.g. zidovudine, saquinavir, indinavir, efavirenz) (see also section 4.3 &ldquo;Contraindications):<br />Rifampicin 600 mg daily reduced zidovudine exposure (AUC) by 47% via induction of zidovudine glucuronidation and amination metabolism pathways;<br />Rifampicin 600 mg daily reduced saquinavir exposure (AUC) by 70% in healthy volunteers and by 47% in HIV-infected patients most likely via induction of CYP3A4 and possibly P-gp pathways;<br />Rifampicin 600 mg daily reduced efavirenz exposure (AUC) by 60% primarily via induction of efavirenz CYP2B6-mediated 8-hydroxylation pathway.</p><p>Hepatitis-C antiviral drugs (e.g. daclatasvir, simeprevir, sofosbuvir, telaprevir):<br />The hepatitis C antivirals are cleared by various drug metabolizing enzymes and transporters which are susceptible to induction by multiple dose rifampicin.<br />Rifampicin 600 mg daily reduced the exposure (AUC) of daclatasvir by 79%, simeprevir by 48%, sofosbuvir by 77% and telaprevir by 92% compared to control subjects.<br />Concurrent use of treatment of hepatitis-C antiviral drugs and rifampicin should be avoided.<br />Antifungals<br />Antifungals (e.g. fluconazole, itraconazole, ketoconazole):<br />Rifampicin 600 mg daily reduced fluconazole exposure (AUC) by approximately 23%, itraconazole by 88% and ketoconazole by about 80%.<br />Antibacterials<br />Chloramphenicol:<br />In two children treated concomitantly with intravenous chloramphenicol and rifampin, peak chloramphenicol serum concentrations were reduced by 85.5% in one patient and by 63.8% in the other.<br />Clarithromycin:<br />Rifampicin 600 mg daily markedly reduced plasma concentrations of clarithromycin and increased clarithromycin metabolite concentrations.<br />Doxycycline:<br />In a group of hospitalized patients rifampicin (10 mg/kg daily) reduced the exposure (AUC) of doxycycline by about 50%.<br />Fluoroquinolones:<br />Rifampicin 900 mg daily modestly reduced the AUC of perfloxacin by about 35%. Rifampicin 450 mg to 600 mg daily has been shown to reduce the exposure (AUC) of moxifloxacin by about 30%.<br />Telithromycin:<br />Telithromycin is metabolized primarily by CYP3A4. Rifampicin 600 mg daily reduced telithromycin exposure (AUC) by 86%.<br />Antimicrobacterials<br />Dapsone:<br />In a clinical probe cocktail study, rifampicin 600 mg daily, increased the metabolism of dapsone via induction of CYP2C9, CYP2E1 and CYP3A4.<br />ANTIEPILEPTICS<br />Anticonvulsants (e.g. phenytoin):<br />Phenytoin is metabolized mainly by CYP2C9/2C19. Rifampicin 450 mg daily doubled the clearance of phenytoin and reduced the half-life by about 50%.<br />Barbiturates:<br />Rifampicin has been shown to increase hexobarbital metabolic clearance by 2- to 3-fold in healthy volunteers and patients, and to significantly decrease hexobarbital half-life.<br />ANTIPSYCHOTICS<br />Antipsychotics (e.g. haloperidol):<br />Coadministration of rifampicin to schizophrenic patients receiving haloperidol decreased haloperidol trough concentrations up to 70%.<br />Benzodiazepines (e.g. diazepam):<br />Rifampicin 600 and 1200 mg daily increased the clearance of diazepam by 60% and 98%, respectively.<br />Benzodiazepine-related drugs (e.g. zopiclone, zolpidem):<br />Rifampicin 600 mg daily reduced the exposure (AUC) of zopiclone by 82% and of zolpidem by 27%.</p><p>Tricyclic antidepressants (e.g. nortriptyline):<br />Rifampicin 600 mg daily as part of a tuberculosis treatment regimen that included isoniazid 300 mg daily, pyrazinamide 500 mg 3x per day and pyridoxine 25 mg was associated with higher than expected doses of nortriptyline were required to obtain a therapeutic drug level. Following the discontinuation of rifampicin, the patient became drowsy and the serum nortriptyline levels rose precipitously (3-fold) into the toxic range.<br />CARDIOVASCULAR SYSTEM<br />Substances that act on the renin-angiotensin system, ACE inhibitors<br />Enalapril:<br />Dosage adjustments should be made if indicated by the patient&#39;s clinical condition.<br />Antiarrhythmics (e.g. disopyramide, mexiletine, quinidine, propafenone, tocainide):<br />Rifampicin 600 mg daily reduced the exposure (AUC) of mexiltine by 41%, quinidine by about 80%, propafenone by 87%, and tocainide by 25%.<br />Beta-blockers:<br />Rifampicin 600 mg daily reduced the exposure (AUC) of metoprolol by 33% and increased the clearance of propranolol by 169%<br />Calcium channel blockers (e.g. diltiazem, nifedipine, verapamil):<br />Calcium channel blockers are primarily substrates of CYP3A4.<br />Rifampicin 1200 mg administered as a single oral dose 8 h before administering a single oral dose of nifedipine 10 mg reduced nifedipine exposure (AUC) by 64%.<br />Rifampicin 600 mg daily reduced the exposure (AUC) of verapamil by 93%.<br />Cardiac glycosides:<br />Digoxin is a clinical index substrate for P-gp activity.<br />Rifampicin 600 mg daily reduced the bioavailability of oral digoxin by 30% and increased intestinal P-gp content 3.5-fold, which correlated with the AUC after oral digoxin.<br />Several reports have been published regarding the interaction of digitoxin and rifampicin. Decreased serum digitoxin levels were observed during antituberculosis therapy with rifampicin-isoniazid-ethambutol or with rifampicin alone; serum digitoxin levels decreased by 53% and 54% respectively.<br />Angiotensin-II antagonists<br />Losartan:<br />Losartan is metabolized by CYP2C9 and CYP3A4 to an active metabolite, E3174, which has greater antihypertensive activity than the parent compound.<br />Rifampin 600 mg daily reduced the exposure (AUC) of losartan by 35% and E3174 by 40%. Losartan oral clearance was increased by 44%. The half-life values of both compounds were decreased by 50%.<br />Statins metabolized by CYP3A4:<br />Simvastatin is a clinical index substrate of CYP3A4.<br />Rifampicin 600 mg daily reduced simvastatin exposure (AUC) by 87% compared to placebo. Because the elimination half-life of simvastatin was not affected by rifampicin, induction of the CYP3A4-mediated first-pass metabolism of simvastatin in the intestine and the liver probably explains this interaction.<br />Clofibrate:<br />Rifampicin 600 mg daily significantly reduced steady-state plasma concentrations of clofibrate&rsquo;s main circulating metabolite, chlorophenoxyisobutyric acid (CPIB), from 50 micrograms/mL to 33 micrograms/mL. Although CPIB plasma half-life of individual subjects was decreased during rifampicin treatment, the change was not significant.<br />ANTITHROMBOTICS<br />Oral anticoagulants (e.g. warfarin):<br />S-Warfarin is a clinical index substrate for CYP2C9. Rifampicin 600 mg daily reduced the exposure (AUC) of S-warfarin by 74%.</p><p>ANALGESICS<br />Narcotic analgesics:<br />Various studies and case reports have been reviewed for rifampicin and opioid analgesics.<br />Rifampin 600 mg daily decreased the mean AUC for IV and oral oxycodone by 53% and 86% respectively, while oral oxycodone mean bioavailability decreased by 70%.<br />Rifampicin 600 mg daily reduced morphine Cmax by 41% and AUC by 28%. The analgesic effect of morphine must be monitored and morphine doses adjusted during and after rifampicin treatment.<br />Methadone:<br />Methadone is predominantly metabolized by CYP2B6 and CYP3A4.<br />Rifampin 600 mg daily reduced the oral bioavailability of methadone from 70% to 50%.<br />HORMONES AND OTHER ENDOCRINE THERAPIES<br />Systemic hormonal contraceptives including estrogens and progestins:<br />Rifampicin treatment reduces the systemic exposure of oral contraceptives.<br />Patients using systemic hormonal contraceptives should be advised to change to non-hormonal methods of birth control during rifampicin therapy.<br />Antiestrogens (e.g. tamoxifen, toremifene):<br />Tamoxifen and toremifen are predominantly substrates of CYP3A4.<br />Rifampicin 600 mg daily reduced the systemic exposure (AUC) of tamoxifen by 86% and of toremifen by 87%.<br />Corticosteroids:<br />Numerous cases appear in the literature describing a decrease in glucocorticoid effect when rifampicin is prescribed concurrently. The literature contains reports of acute adrenal crisis or adrenal insufficiency induced by the combination of rifampicin-isoniazid-ethambutol or rifampicin-isonizid in patients with Addison&rsquo;s disease. In patients receiving concomitant rifampicin, prednisolone AUC was reduced by 48% to 66% and clearance was increased by 45% to 91%.<br />Levothyroxine:<br />Rifampicin 600 mg daily was administered to a patient previously treated with levothyroxine. Approximately 2 weeks after initiation of rifampicin, thyroid stimulating hormone (TSH) concentration increased by 202% compared to the pretreatment concentration. TSH concentration returned to normal 9 days after discontinuation of rifampin.<br />GASTROINTESTINAL SYSTEM AND BIOTRANSFORMATION<br />Selective 5-HT3 receptor antagonists (e.g. ondansetron):<br />Ondansetron is metabolized by multiple CYP enzymes.<br />Rifampicin 600 mg daily reduced the exposure (AUC) of orally administered ondansetron by 65% compared with placebo and the elimination half-life (t&frac12;) by 38%.<br />The oral bioavailability of ondansetron was reduced from 60% to 40%.<br />Thiazolidinediones (e.g. rosiglitazone):<br />Rosiglitazone is primarily metabolized by CYP2C8 and to a lesser extent by CYP2C9.<br />Rifampicin 600 mg daily increased rosiglitazone apparent oral clearance by 3-fold, reduced rosiglitazone exposure (AUC) by 65%, and reduced elimination half-life from 3.9 to 1.5 h.<br />Oral hypoglycemic agents (e.g. sulfonylureas):<br />Sulfonylureas are primarily substrates of CYP2C9.<br />Rifampicin 600 mg daily reduced the exposure (AUC) of glyburide by 39% and of glipizide by 22%, and reduced the half-life of both drugs. It is probable that the blood glucose-lowering effect of glyburide is reduced during concomitant treatment with rifampin.<br />ANTINEOPLASTICS<br />Irinotecan:<br />Irinotecan is extensively metabolized by various enzyme systems, including carboxylesterases, UGT, and CYP3A4.</p><p>Rifampicin 450 mg/day was administered to a patient as part of an antibiotic regimen including isoniazid (300 mg/day) and streptomycin (0.5 g/day im). Although there was no change in irinotecan exposure (AUC), irinotecan active metabolite exposure (AUC) decreased by 20% and its glucuronide metabolite decreased by 58.8%, possibly via induction of CYP3A4.<br />IMMUNOSUPPRESANTS<br />Immunosuppressive agents (e.g. ciclosporin, tacrolimus):<br />Ciclosporin and tacrolimus are substrates of CYP3A4 and P-gp.<br />In 6 healthy volunteers oral bioavailability of ciclosporin was reduced from 33% to 9% with coadministration of rifampicin 600 mg daily. In 4 kidney transplant patients, coadministration of rifampicin 600 mg daily reduced the exposure of ciclosporin (AUC) by approximately 60%.<br />In 6 healthy volunteers oral bioavailability of tacrolimus was reduced by 51% with coadministration of rifampicin 600 mg daily via induction of CYP3A4 and P-gp.<br />ANTIPARASITIC DRUGS<br />Praziquantel:<br />Praziquantel is extensively metabolized by CYP enzymes.<br />Rifampicin 600 mg daily reduced plasma concentrations of praziquantel to below detectable levels in 7 of 10 subjects administered single dose praziquantel; of the 3 subjects with detectable concentrations, praziquantel exposure (AUC) was reduced by 85%.<br />In the same study, rifampicin reduced multiple dose praziquantel concentrations below detectable levels in 5 of 10 subjects; of the 5 subjects with detectable concentrations, praziquantel exposure was reduced by 80%.<br />Quinine:<br />Quinine is mainly metabolized by CYP3A4.<br />Rifampicin 600 mg daily increased quinine clearance by 6.9-fold and reduced quinine exposure (AUC) and half-life.<br />RESPIRATORY SYSTEM<br />Other drugs for systemic use to treat obstructive respiratory disorders, xanthine derivatives:<br />Theophylline:<br />Theophylline is a clinical index inhibitor of CYP1A2.<br />Rifampicin 600 mg daily increased theophylline clearance by 40%, reduced theophylline exposure (AUC) by 27%, and reduced elimination half-life by 30%.<br />Effect of other medicinal products on Rifadin<br />Concomitant antacid administration may reduce the absorption of Rifadin. Daily doses of Rifadin should be given at least 1 hour before the ingestion of antacids.<br />Other drug interactions with Rifadin<br />When atovaquone and rifampicin were taken concomitantly, decreased concentrations of atovaquone and increased concentrations of rifampicin were observed.<br />The concomitant administration of rifampicin with para-aminosalicylic acid (PAS) in formulations containing the excipient bentonite may reduce blood levels of rifampicin. The two drugs should be administered at an interval of at least 8 hours.<br />Interference with diagnostic and laboratory tests<br />Therapeutic levels of Rifadin have been shown to inhibit standard microbiological assays for serum folate and vitamin B12. Thus, alternative assay methods should be considered. Transient elevation of serum bilirubin has also been observed (see section 4.4). Rifadin may impair biliary excretion of contrast media used for visualization of the gallbladder, due to competition for biliary excretion. Therefore, these tests should be performed before the morning dose of Rifadin.<br />Cross-reactivity and false-positive urine screening tests for opiates have been reported in patients receiving rifampicin when using the KIMS (Kinetic Interaction of Microparticles in Solution) method (e.g. Abuscreen OnLine opiates assay; Roche Diagnostic Systems). Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish rifampicin from opiates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no well-controlled studies with rifampicin in pregnant women.<br />Rifampicin has been shown to be teratogenic in rodents when given in large doses.<br />Although Rifadin has been reported to cross the placental barrier and appear in cord blood, the effect of the drug, alone or in combination with other antituberculosis drugs, on the human fetus is not known.<br />When administered during the last few weeks of pregnancy, rifampicin can cause post-natal hemorrhages in the mother and infant, for which treatment with vitamin K may be indicated.<br />Therefore, this antibiotic should be used in pregnant women or in women of childbearing potential only if the potential benefit justifies the potential risk to the fetus.<br />Breast-feeding<br />Rifampicin is excreted in breast milk. Therefore, this antibiotic should be used in a nursing mother only if the potential benefit to the patient outweighs the potential risk to the infant.<br />Fertility<br />No data are available concerning the long-term effects on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rifadin may cause undesirable effects which may reduce the capacity for the completion of certain tasks (see section 4.8). Patients should be informed that these undesirable effects may occur, and that if they experience these symptoms, consideration should be given not to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are defined by System Organ Class and by frequency using the following convention: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1 000 to &lt; 1/100), rare ( 1/10 000 to &lt; 1/1 000), very rare (&lt; 1/10 000), not known (cannot be estimated from the available data).<br />Infections and infestations<br />Not known: pseudomembranous colitis, influenza.<br />Blood and lymphatic system disorders<br />Common: thrombocytopenia with or without purpura, usually associated with intermittent therapy, but reversible if the drug is discontinued as soon as purpura occurs.<br />Uncommon: leukopenia.<br />Not known: disseminated intravascular coagulation, eosinophilia, agranulocytosis, hemolytic anemia, vitamin K dependent blood clotting disorders.<br />Immune system disorders<br />Not known: anaphylactic reactions.<br />Endocrine disorders<br />Not known: adrenal insufficiency in patients with compromised adrenal function.<br />Metabolism and nutrition disorders<br />Not known: decreased appetite.<br />Psychiatric disorders<br />Not known: psychotic disorders.<br />Nervous system disorders<br />Common: headache, dizziness.<br />Not known: cerebral hemorrhage and fatalities have been reported when rifampicin administration has been continued or resumed after the appearance of purpura.<br />Eye disorders<br />Not known: change in tear color.</p><p>Vascular disorders<br />Not known: shock, flushing, vasculitis, bleeding.<br />Respiratory, thoracic and mediastinal disorders<br />Not known: dyspnea, wheezing, change in sputum color.<br />Gastrointestinal disorders<br />Common: nausea, vomiting.<br />Uncommon: diarrhea.<br />Not known: gastrointestinal disorders, abdominal discomfort, change in teeth color (which may be permanent).<br />Hepatobiliary disorders<br />Not known: hepatitis, hyperbilirubinemia (see section 4.4).<br />Skin and subcutaneous tissue disorders<br />Not known: erythema multiforme, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS) (see section 4.4), skin reactions, pruritus, pruritic rash, urticaria, allergic dermatitis, pemphigus, change in sweat color.<br />Musculoskeletal and connective tissue disorders<br />Not known: muscle weakness, myopathy, bone pain.<br />Renal and urinary disorders<br />Not known: acute kidney injury usually due to renal tubular necrosis or tubulointerstitial nephritis, chromaturia.<br />Pregnancy, puerperium and perinatal conditions<br />Not known: post-partum hemorrhage, fetal-maternal hemorrhage.<br />Reproductive system and breast disorders<br />Not known: menstrual disorders.<br />Congenital, familial and genetic disorders<br />Not known: porphyria.<br />General disorders and administration site conditions<br />Very common: pyrexia, chills.<br />Not known: edema.<br />Investigations<br />Common: increased blood bilirubin, increased aspartate aminotransferase, increased alanine aminotransferase.<br />Not known: decreased arterial blood pressure, increased blood creatinine, increased hepatic enzymes.<br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; SFDA call center : 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Nausea, vomiting, abdominal pain, pruritus, headache and increasing lethargy may occur within a short time after acute ingestion; unconsciousness may occur when there is severe hepatic disease. Transient increases in liver enzymes and/or bilirubin may occur. Brownish-red or orange discoloration of the skin, urine, sweat, saliva, tears and feces will occur, and its intensity is proportional to the amount ingested. Facial or periorbital edema has also been reported in pediatric patients.</p><p>Hypotension, sinus tachycardia, ventricular arrhythmias, seizures and cardiac arrest were reported in some fatal cases.<br />The minimum acute lethal or toxic dose is not well established. However, nonfatal acute overdoses in adults have been reported with doses ranging from 9 to 12 g rifampicin. Fatal acute overdoses in adults have been reported with doses ranging from 14-60 g. Alcohol or a history of alcohol abuse was involved in some of the fatal and nonfatal reports.<br />Nonfatal overdoses in pediatric patients ages 1 to 4 years old of 100 mg/kg for one to two doses has been reported.<br />Management<br />Intensive supportive measures should be instituted and individual symptoms treated as they arise. Since nausea and vomiting are likely to be present, gastric lavage is probably preferable to induction of emesis. Following evacuation of the gastric contents, the instillation of activated charcoal slurry into the stomach may help absorb any remaining drug from the gastrointestinal tract. Antiemetic medication may b.e required to control severe nausea and vomiting. Active diuresis (with measured intake and output) will help promote excretion of the drug. Hemodialysis may be of value in some patients.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycobacterials, antibiotics; ATC code: J04AB02.<br />Rifadin inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.<br />Rifadin is particularly active against rapidly growing extracellular microorganisms, but it also has intracellular antibacterial activity against slow- and intermittently-growing M. tuberculosis.<br />It is also active in vitro against Mycobacterium avium complex, M. kansasii, and M. leprae.<br />Rifadin is active in vitro against a variety of gram-positive and gram-negative microorganisms. The sensitive microorganisms include Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Proteus spp, Staphylococcus epidermidis, H. influenzae, E. coli, Ps. aeruginosa, Legionella pneumophila, Brucella spp. and Streptococcus pyogenes. Both penicillinase-producing and non-penicillinase-producing staphylococci and beta-lactam-resistant staphylococci are susceptible to Rifadin.<br />Cross-resistance to rifampicin has only been shown with other rifamycins.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Orally administered Rifadin is rapidly absorbed from the gastrointestinal tract. Peak plasma levels in adults and children vary widely from individual to individual. Peak serum concentrations of approximately 10 mcg/mL occur 2-4 hours after oral administration of a dose of 10 mg/kg body weight on an empty stomach. Absorption of Rifadin is reduced when the drug is ingested with food.<br />After intravenous administration of a 300 or 600 mg dose infused over 30 minutes to healthy male volunteers (n = 12), peak plasma concentrations were 9.0 and 17.5 mcg/mL respectively. The mean plasma concentration in these volunteers remained detectable for 8 and 12 hours respectively.<br />Pharmacokinetics (oral and intravenous) in children is similar to adults.<br />In normal subjects, the biological half-life of Rifadin in serum is approximately 3 hours after a 600 mg dose and increases to 5.1 hours after a 900 mg dose. With repeated administration, the half-life decreases and reaches mean values of approximately 2-3 hours.<br />At a dose of 600 mg/day, the half-life is similar in patients with renal failure and consequently, no dose adjustment is required.<br />Elimination<br />After absorption, Rifadin (oral or intravenous) is rapidly eliminated in the bile and an enterohepatic circulation ensues. During this process, Rifadin undergoes progressive deacetylation, so that nearly all the drug in the bile is acetylated in 6 hours. This metabolite retains antibacterial activity.<br />Intestinal reabsorption is reduced by deacetylation and elimination is facilitated. Approximately 30% of a dose is excreted in the urine, with about half of this being unchanged drug.</p><p>Distribution<br />Rifadin is widely distributed throughout the body. It is present in effective concentrations in many organs and body fluids, including cerebrospinal fluid.<br />Rifadin is about 80% protein-bound. Most of the unbound fraction is not ionized and therefore diffuses freely into tissues.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenicity<br />There are no human data on the long-term potential for carcinogenicity. A few cases of worsening of lung carcinoma have been reported in man, but a causal relationship with the drug has not been established. An increase in the incidence of hepatomas in female mice (of a strain known to be particularly susceptible to the spontaneous development of hepatomas) was observed when Rifadin was administered at doses 2 to 10 times the average human dose for 60 weeks followed by an observation period of 46 weeks. No evidence of carcinogenicity was found in male mice of the same strain or in rats under similar experimental conditions.<br />Rifadin has been reported to possess immunosuppressive potential in rabbits, mice, rats, guinea pigs, human lymphocytes in vitro and humans.<br />Antitumor activity in vitro has also been shown with Rifadin.<br />Mutagenicity<br />There are no human data on the long-term potential for mutagenicity. There was no evidence of mutagenicity in bacteria, Drosophila melanogaster or mice. An increase in chromatid breaks was noted when human blood cell cultures were treated with Rifadin. Increased frequency of chromosome aberrations was observed in vitro in lymphocytes obtained from patients treated with combinations of Rifadin, isoniazid and pyrazinamide and combinations of streptomycin, Rifadin, isoniazid and pyrazinamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rifadin hard capsules<br />Maize starch, magnesium stearate, gelatin, erythrosine (E 127), indigo carmine (E 132), titanium dioxide (E 171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem and rifampicin (6 mg/mL in normal saline) during simulated Y-site administration. Rifadin solution for infusion must not be diluted in 5% sodium bicarbonate solution or 1/6 mol sodium lactate as precipitation may occur.<br />5% glucose or normal saline solutions are recommended to dilute the reconstituted solution. Use of other infusion vehicles is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rifadin hard capsules, coated tablets and syrup<br />Do not store above 25 &ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Box of capsules in blisters<br />150 mg hard capsules: 8 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi S.p.A.
– Viale L. Bodio, 37/B – 20158 Milan, Italy
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>